Royalty Pharma plc Class A Ordinary Shares
RPRX · NASDAQ-GS
- $66.52
- $38.18B
- Open
- —
- —
- $66.12 - $67.44
- $36.03 - $67.71
- —
- —
- 3.15M
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires rights to future royalties on biopharmaceutical products, providing capital to drug developers and other royalty holders in return for a share of future product revenues. It earns chiefly from royalty receipts tied to medicines, rather than by discovering, manufacturing and selling drugs itself; the supplied evidence does not break revenue into segments or quantify individual royalty contributions. Its counterparties include biopharmaceutical companies and other holders of drug royalties, while the underlying medicines serve patients through healthcare providers and payers. Royalty Pharma reports FY2025 revenue of $2.4 billion and net income of $0.8 billion.
Notable Price Movement
- Sep 28 - Oct 2$57.161.80%
RPRX fell $0.07, or 0.12%, from $58.44 to $58.37 over the quoted week. It first rose to $58.52 on Sep. 22, then dropped to $57.65 on Sep. 23 before recovering to $58.29 on Sep. 24; it eased to $58.21 on Sep. 25 and closed at $58.37 on Sep. 28. The supplied evidence does not tie that reversal or the nearly flat finish to a company-specific catalyst: MarketBeat discussed management's AI capabilities, China presence and monitoring of biopharma policy changes, while a separate MarketBeat headline reported an EVP stock sale valued at $5.853 million, but neither snippet links these items to the week's trading. No market-wide driver is identified in the evidence.
- Aug 3-7$56.772.84%
Royalty Pharma fell $2.49, or 4.15%, from $59.97 to $57.48 over the period, extending losses through four consecutive closes before a modest rebound on August 4. The stock declined $0.79 on July 29, $0.16 on July 30, and $0.59 on July 31, then dropped another $1.26 on August 3 before recovering $0.31. Supplied evidence does not identify a broad-market catalyst or establish the exact timing of the company-specific news relative to trading. The later Q2 update was mixed: earnings and revenue beat estimates by 3.94% and 1.52%, adjusted EBITDA rose to $736 million from $633 million, and 2026 portfolio-receipts guidance increased, but net income fell to $18 million from $32 million.
